Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

GE Healthcare Launches Biacore™ T200 Software v.2.0

Published: Friday, July 12, 2013
Last Updated: Friday, July 12, 2013
Bookmark and Share
New software expands Biacore T200’s capabilities for highly sensitive, focused screening.

Biacore™ T200 Software v.2.0 enhances the capabilities of Biacore T200, offering researchers a flexible and powerful tool for efficient processing of molecular interaction data.

Together, they facilitate label-free screening of low molecular weight compounds and low abundance proteins, giving detailed binding profiles on molecule-drug candidate mechanisms of action that ultimately assist in earlier lead selection and optimization.

The new software simplifies and speeds up the generation and transformation of raw label-free interaction data into high-quality information, reducing the time needed for screening and hit validation.

Versatile, easy-to-use wizards guide assay set up, and options are available for designing custom assays, making Biacore T200 ideal for a multi-user environment.

The new software encompasses algorithms for efficient ranking and qualification of binders versus non-binders, and enables comparison of datasets through normalization of sample responses by a number of means.

By performing detailed evaluation of a single sample or co-evaluating up to 5000 single-concentration samples from multiple runs with the same ease, Biacore™ T200 Software v.2.0 significantly reduces the time required for evaluation of large lead series.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

GE Healthcare’s 2012 Cell Imaging Competition - Voting Opens to Celebrate Art, Science and Discovery
Competition features both high-content analysis and high- and super-resolution microscopy cell images for the first time.
Thursday, November 22, 2012
GE Healthcare to Invest $1 Billion in New Oncology Solutions
Expanding advanced cancer diagnostic and molecular imaging capabilities.
Saturday, September 17, 2011
The Inaugural Winner of GE Healthcare High-Content Analysis (HCA) Award Achieved 20-Fold Increase in Throughput
The inaugural winner of the first GE Healthcare HCA Award has been announced. Supported by BioTechniques, the Award recognizes the outstanding contribution of HCA to scientific understanding and celebrates its positive impact on data quality and quantity, resulting in increased productivity, deeper insights and better decisions.
Friday, October 29, 2010
GE Healthcare to Host DiPIA 2010 - Developments in Protein Interaction Analysis
Addressing functional characterization of proteins and their interactions.
Thursday, July 22, 2010
GE Healthcare Launches High Content Analysis Award
The award recognizes the work of researchers using GE Healthcare’s IN Cell Analyzer.
Tuesday, May 04, 2010
IN Cell Image Competition 2009/2010 Voting Opens
Vote for your favorite image and receive a complementary 2010 calendar!
Tuesday, December 01, 2009
GE Healthcare Forms Strategic Alliance with FUJIFILM in Life Sciences
GE Healthcare announced that it has entered into a Strategic Alliance Agreement with FUJIFILM Corporation. Under the alliance, Fujifilm will develop, manufacture and supply advanced biomolecular imaging systems to GE Healthcare.
Thursday, May 28, 2009
Winners of GE Healthcare’s IN Cell Image Competition Announced
Each of the three winners, from Asia, Europe and North America, will be rewarded with a trip to New York City in March.
Wednesday, January 14, 2009
Scientific News
New Cancer Drug Target in Dual-Function Protein
Scientists at The Scripps Research Institute (TSRI) have identified a protein that launches cancer growth and appears to contribute to higher mortality in breast cancer patients.
Penn State, TB Alliance, and GSK Partner To Discover New Treatments For TB
A new collaboration between TB Alliance, GSK, and scientists in the Eberly College of Science seeks to find new small molecules that can be used to create antibiotics in the fight against tuberculosis (TB).
Molecular Map Provides Clues To Zinc-Related Diseases
Mapping the molecular structure where medicine goes to work is a crucial step toward drug discovery against deadly diseases.
Platelets are the Pathfinders for Leukocyte Extravasation During Inflammation
Findings from the study could help in the prevention and treatment of inflammatory pathologies.
Genetic Research Can Significantly Improve Drug Development
With drug development costs topping $1.2bn (£850 million) to get a single treatment to the point it can be sold and used in the clinic, could genetic analysis save hundreds of millions of dollars?
New Method Opens Door to Development of Many New Medicines
Findings from TSRI reveal human proteins are better drug targets than previously thought.
Diagnosing Systemic Infections Quickly, Reliably
Team develop rapid and specific diagnostic assay that could help physicians decide within an hour whether a patient has a systemic infection and should be hospitalized for aggressive intervention therapy.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Blood Test That Detects Early Alzheimer’s Disease
A research team, led by Dr. Robert Nagele from Rowan University School of Osteopathic Medicine and Durin Technologies, Inc., has announced the development of a blood test that leverages the body’s immune response system to detect an early stage of Alzheimer’s disease – referred to as the mild cognitive impairment (MCI) stage – with unparalleled accuracy.
A New Approach to Chemical Synthesis
Communesins, originally found in fungus, could hold potential as cancer drugs.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!